Preview

Rational Pharmacotherapy in Cardiology

Advanced search

High residual platelet reactivity during dual antiplatelet therapy, found by optical aggregometry and the rate of atherothrombotic complications after coronary artery stenting in patients with ischemic heart disease in clinical practice

https://doi.org/10.20996/1819-6446-2016-12-4-385-390

Full Text:

Abstract

Aim. To study the prevalence of high residual platelet reactivity (HRPR) during the dual antiplatelet therapy (DAT) with acetylsalicylic acid (ASA) and clopidogrel by optical aggregometry in patients with ischemic heart disease (IHD) after percutaneous transluminal coronary angioplasty (PTCA) in clinical practice, as well as to determine its value for the prediction of clinical course and outcome of disease.

Material and methods. Patients after PTCA and during DAT were included into the study. Evaluation of the functional activity of platelets by optical aggregometry was performed in all patients at baseline. Resistance to ASA, clopidogrel and DAT were detected. Endpoints included cases of repeated atherothrombotic events (sudden cardiac death, myocardial infarction, unstable angina, ischemic stroke, stent thrombosis). Adherence to therapy was evaluated by Morisky-Green test.

Results. 97 patients were included into the final analysis. The risk of myocardial infarction or unstable angina pectoris in the ASA-resistant patients was significantly higher than this in the DAT-sensitive patients [relative risk (RR)=7.68; 95% confidence interval (CI) 2.8-20.54; p=0.045]. Maximum RR for stent thrombosis was in clopidogrel-resistant (RR=7.1; 95% CI 1.41-35.82; p=0.0485) and DAT-resistant patients (RR=12.8; 95% CI 4.5-36.38; p=0.0491), compared with patients with a sensitivity to antiplatelet therapy. DAT-resistance was associated with a higher RR of the combined endpoint, compared with the sensitivity to antiplatelet therapy (RR=10.24; 95% CI 3.96-26.5; p=0.046]), and have a tendency to association with increased risk of combined endpoint compared with isolated ASA-resistance (RR=1.3; 95% CI 0.68-2.6; p=0.081).

Conclusion. HRPR during DAT is common in clinical practice in patients with ischemic heart disease after PTCA. Routine use of optical aggregometry in DAT may help to identify patients with an increased risk of thrombotic events in the postoperative period and to assign them an alternative antiplatelet therapy.

About the Authors

N. F. Puchinyan
Research Institute for Cardiology, Saratov State Medical University named after V.I. Razumovsky
Russian Federation
Bolshaya Kazachia ul. 112, Saratov, 410012


N. V. Furman
Research Institute for Cardiology, Saratov State Medical University named after V.I. Razumovsky
Russian Federation
Bolshaya Kazachia ul. 112, Saratov, 410012


P. V. Dolotovskaya
Research Institute for Cardiology, Saratov State Medical University named after V.I. Razumovsky
Russian Federation
Bolshaya Kazachia ul. 112, Saratov, 410012


L. L. Malinova
Research Institute for Cardiology, Saratov State Medical University named after V.I. Razumovsky
Russian Federation
Bolshaya Kazachia ul. 112, Saratov, 410012


References

1. Patrono C., Andreotti F., Arnesen H. et al Antiplatelet Agents for the Treatment and Prevention of Atherothrombosis. Eur Heart J 2011; 32(23): 2922-32.

2. Eikelboom J.W., Hirsh J., Spencer F.A., et al. Antiplatelet Drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 2012; 141(2)(Suppl): e89S-e119S.

3. Sabouret P., Rushton-Smith S.K., Kerneis M. et al. Dual antiplatelet therapy: optimal timing, management, and duration. Eur Heart J 2015; 1: 198-204.

4. The role of testing platelet functional activity in the prevention of cardiovascular events in patients receiving antiplatelet therapy. Conclusion of the Council of Experts. Rational Pharmacotherapy in Cardiology 2014; 10 (6): 679-87. In Russian (Роль тестирования функциональной активности тромбоцитов в профилактике сердечно-сосудистых осложнений у больных, получающих антитромбоцитарную терапию. Заключение Совета Экспертов. Рациональная Фармакотерапия в Кардиологии 2014; 10(6): 679-87).

5. Greenstein JI, Kosinova AA, Greenstein IY. Monitoring antiplatelet therapy: a crisis of confidence or the search for new solutions? Rational Pharmacotherapy in Cardiology 2013; 9 (6): 682-9. In Russian (Гринштейн Ю.И., Косинова А.А., Гринштейн И.Ю. Контроль антитромбоцитарной терапии: кризис доверия или поиск новых решений? Рациональная Фармакотерапия в Кардиологии 2013; 9(6): 682-9).

6. Komarov AL, Panchenko EP. Testing the function of platelets to assess the risk of thrombosis and bleeding in patients with coronary artery disease treated with antiplatelet agents. Russian Cardiology Journal 2015; 3 (119): 25-34. In Russian (Комаров А.Л., Панченко Е.П. Тестирование функции тромбоцитов для оценки риска тромбозов и кровотечений у больных ИБС, получающих антиагреганты. Российский Кардиологический Журнал 2015; 3(119): 25-34).

7. Gurbel P.A., Becker R.C., Mann K.G. et al. Platelet Function Monitoring in Patients With Coronary Artery Disease. J Am Coll Cardiol 2007; 50: 1822-34.

8. Aradi D., Kirtane A., Bonello L. et al. Bleeding and stent thrombosis on P2Y12 inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015; 36: 1762-71.

9. Tantry U.S., Bonello L., Aradi D. et al. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. J Am Coll Cardiol 2013; 62: 2261-73.

10. Aradi D., Storey R.F., Komócsi A. et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 2014; 35: 209-15.

11. Bonello L., Tantry U.S., Marcucci R. et al. Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56(12): 919-33.

12. De Luca L., Leonardi S., Smecca I. M. et al. Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: insights from the EYESHOT study. Eur Heart J 2015; 1: 168-78.

13. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24(1):67-74.

14. Mason PJ, Jacobs AK, Freedman JE. Aspirin Resistance and Atherothrombotic Disease. J Am Coll Cardiol 2005; 46: 986-93.

15. Gum P.A., Kottke-Marchant K., Welsh P.A. et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.J Am Coll Cardiol 2003, 41: 961-5.

16. Eikelboom J.W., Hirsh J., Weitz J.I. et al. Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5.

17. Martynov AI, Akatova EV, Urlaeva IV, Nikolin OP. True resistance to aspirin and psevdorezistentnost. Rational Pharmacotherapy in Cardiology 2013; 9 (3): 301-5. In Russian (Мартынов А.И., Акатова Е.В., Урлаева И.В., Николин О.П. Истинная резистентность и псевдорезистентность к аспирину. Рациональная Фармакотерапия в Кардиологии 2013; 9(3): 301-5).

18. Sulimov VA, Moroz EV. Resistance to antiplatelet drugs (aspirin, clopidogrel) in patients undergoing elective coronary stenting. Rational Pharmacotherapy in Cardiology 2012; 8 (1): 23-30. In Russian (Сулимов В.А., Мороз Е.В. Резистентность к антитромбоцитарным препаратам (аспирину, клопидогрелу) у пациентов, подвергающихся элективному стентированию коронарных артерий. Рациональная Фармакотерапия в Кардиологии 2012; 8(1): 23-30).

19. Lev E.I., Patel R.T., Maresh K.J. et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J. Am. Coll. Cardiol 2006; 47: 27-33.

20. Bliden K.P., DiChiara J., Tantry U.S. et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007; 49: 657-66.

21. Kuliczkowski W., Witkowski A., Polonski L. et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of CardiovascularInterventions ofthe Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009; 30: 426-35.

22. AynetdinovaDH, Udovychenko AE, Sulimov VA. Resistance to antiplatelet agents in patients with acute coronary syndrome without ST segment elevation. Kardiologiia 2008; 6: 35-8. In Russian (Айнетдинова Д.Х., Удовиченко А.Е., Сулимов В.А. Резистентность к антитромбоцитарным препаратам у больных с острым коронарным синдромом без подъема сегмента ST. Кардиология 2008; 6: 35-8).

23. Buryachkovskaya LI, Uchitel IA, SumarokovAV, Popov EG. Problems of efficiency assessment antiplatelet therapy in clinical practice. Ter Arkhiv 2009; 5: 41-7. In Russian (Бурячковская Л.И., Учитель И.А., Сумароков А.В., Попов Е.Г. Проблемы оценки эффективности дезагрегантной терапии в клинической практике. Терапевтический Архив 2009; 5: 41-7).

24. Frolova NS, Shakhnovich RM, Sirotkina OV, et al. Resistance to clopidogrel in patients with acute coronary syndrome. Ter Arkhiv 2010; 8: 14-22. In Russian (Фролова Н.С., Шахнович Р.М., Сироткина О.В. и др. Резистентность к клопидогрелу у больных с острым коронарным синдромом. Терапевтический Архив 2010; 8: 14-22).

25. Winter M.P., Koziński M., Kubica J., et al. Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. Postepy Kardiol Interwencyjnej 2015; 11(4): 259-80.

26. Aradi D., Collet J.P., Mair J. et al. Platelet function testing in acute cardiac care - is there a role for prediction or prevention of stent thrombosis and bleeding? Thromb Haemost 2015; 113(2): 221-30.

27. Price M.J., Berger P.B., Teirstein P.S. et al. Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. The GRAVITAS Randomized Trial.JAMA 2011; 305(11): 1097-105.

28. Michelson A.D., Frelinger A.L. 3rd, Braunwald E., et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009; 30: 1753-63.

29. Trenk D., Stone G.W., Gawaz M. et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI study. J Am Coll Cardiol 2012; 59(24): 2159-64.

30. Gilyarevsky SR, Orlov VA, Kuzmina IM, LarinAG.Alternative approaches to the use of a two-antiplatelet therapy in patients with acute coronary syndrome: evidence, recommendations and actual practice. Rational Pharmacotherapy in Cardiology 2012; 8 (4): 531-53. In Russian (Гиляревский С.Р., Орлов В.А., Кузьмина И.М., Ларин А.Г. Альтернативные подходы к применению двухкомпонентной антиагрегантной терапии у больных с острым коронарным синдромом: доказательства, рекомендации и реальная практика. Рациональная Фармакотерапия в Кардиологии 2012; 8(4): 531-53).


For citation:


Puchinyan N.F., Furman N.V., Dolotovskaya P.V., Malinova L.L. High residual platelet reactivity during dual antiplatelet therapy, found by optical aggregometry and the rate of atherothrombotic complications after coronary artery stenting in patients with ischemic heart disease in clinical practice. Rational Pharmacotherapy in Cardiology. 2016;12(4):385-390. (In Russ.) https://doi.org/10.20996/1819-6446-2016-12-4-385-390

Views: 377


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)